(19)
(11) EP 3 313 385 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.04.2021 Bulletin 2021/16

(45) Mention of the grant of the patent:
03.03.2021 Bulletin 2021/09

(21) Application number: 16815334.4

(22) Date of filing: 23.06.2016
(51) International Patent Classification (IPC): 
C07F 9/564(2006.01)
A61K 31/06(2006.01)
 A61K 31/04(2006.01)
A61K 33/42(2006.01)
(86) International application number:
PCT/US2016/039092
(87) International publication number:
WO 2016/210175 (29.12.2016 Gazette 2016/52)

(54)

AZIRIDINE CONTAINING DNA ALKYLATING AGENTS

AZIRIDINHALTIGE DNA-ALKYLIERUNGSMITTEL

AGENTS D'ALKYLATION D'ADN CONTENANT DE L'AZIRIDINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 24.06.2015 US 201562184129 P

(43) Date of publication of application:
02.05.2018 Bulletin 2018/18

(60) Divisional application:
21160058.0

(73) Proprietor: ImmunoGenesis, Inc.
Houston TX 77010 (US)

(72) Inventors:
  • MATTEUCCI, Mark
    South San Francisco, CA 94080 (US)
  • CAI, Xiaohong
    South San Francisco, CA 94080 (US)
  • CAO, Yeyu
    South San Francisco, CA 94080 (US)
  • JIAO, Hailong
    South San Francisco, CA 94080 (US)
  • MA, Jing Yuan
    South San Francisco, CA 94080 (US)
  • DUAN, Jian-Xin
    South San Francisco, CA 94080 (US)

(74) Representative: Gibson, Mark 
Sagittarius IP Marlow International Parkway
Marlow SL7 1YL
Marlow SL7 1YL (GB)


(56) References cited: : 
WO-A1-2008/151253
WO-A2-2007/098089
US-A1- 2014 170 240
 WO-A1-2016/145092
US-A1- 2008 269 268
US-A1- 2014 170 240
   
  • K. MISIURA ET AL: "Stereospecific synthesis of chiral metabolites of Ifosfamide and thier determination in the Urine", JOURNAL OF MEDICINAL CHEMISTRY., vol. 26, 1983, pages 674-679, XP002786859, USAMERICAN CHEMICAL SOCIETY. WASHINGTON. ISSN: 0022-2623
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).